Literature DB >> 31647948

Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.

Yu Dong1, Tao Xu2, Shouping Zhong2, Bo Wang3, Huimin Zhang3, Xin Wang2, Peng Wang3, Guangshun Li2, Shuanying Yang4.   

Abstract

AIMS: Circular RNAs (circRNAs) acted as key regulators in the development of various human tumors. Our present study aimed to investigate the role and molecular mechanism of circ_0076305 in regulating cisplatin (DDP) resistance of non-small cell lung cancer (NSCLC). MAIN
METHODS: Using RT-qPCR, the expressions of circ_0076305 in NSCLC tissues and cells (A549, H1650, A549/DDP, H1650/DDP) were measured. Through loss-of-function and overexpression experiments, the role of circ_0076305 in DDP resistance of NSCLC was verified. Inhibitory rate and IC50 for DDP were detected using MTT method after DDP treatment. Western blotting was performed to evaluate protein levels of P-gp and MRP1. The bindings between circ_0076305 and miR-296-5p, as well as miR-296-5p and STAT3 were validated by bioinformatics, CircRIP, Pearson's correlation analysis and luciferase report vector assays. KEY
FINDINGS: Circ_0076305 was upregulated in NSCLC, and more significantly elevated in DDP-resistant NSCLC tissues and cells. Further experiments discovered that circ_0076305 could regulate DDP resistance of NSCLC cells via binding to miR-296-5p. Directly targeted by miR-296-5p, STAT3 hindered the miR-296-5p-induced suppression on DDP resistance. Finally, the expression of circ_0076305 was found to have positive correlation with STAT3, and circ_0076305 was validated to regulate STAT3 via targeting miR-296-5p. SIGNIFICANCE: Our present study illustrated that circ_0076305 regulated STAT3 expression and DDP resistance of NSCLC cells via sponging miR-296-5p. These results suggested knockdown of circ_0076305 might provide an effective approach for NSCLC treatment strategy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Circular RNA; Cisplatin resistance; Non-small cell lung cancer; STAT3; miR-296–5p

Mesh:

Substances:

Year:  2019        PMID: 31647948     DOI: 10.1016/j.lfs.2019.116984

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  37 in total

1.  Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.

Authors:  Changyu Zhu; Xiaolei Jiang; Hua Xiao; Jianmei Guan
Journal:  Biochem Genet       Date:  2022-04-23       Impact factor: 1.890

2.  Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint.

Authors:  Jie Lei; Jianfei Zhu; Bengang Hui; Chenghui Jia; Xiaolong Yan; Tao Jiang; Xiaoping Wang
Journal:  Cancer Immunol Immunother       Date:  2022-06-24       Impact factor: 6.968

3.  Circ-PGC increases the expression of FOXR2 by targeting miR-532-3p to promote the development of non-small cell lung cancer.

Authors:  Daokui Xia; Zhen Chen; Quan Liu
Journal:  Cell Cycle       Date:  2021-09-08       Impact factor: 5.173

4.  Circular RNA EPB41 expression predicts unfavorable prognoses in NSCLC by regulating miR-486-3p/eIF5A axis-mediated stemness.

Authors:  Mingming Jin; Xiyu Liu; Yue Wu; Yuqing Lou; Xue Li; Gang Huang
Journal:  Cancer Cell Int       Date:  2022-06-20       Impact factor: 6.429

5.  CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC).

Authors:  Yongsheng Zhao; Renyan Zheng; Jian Chen; Dong Ning
Journal:  Cancer Cell Int       Date:  2020-07-06       Impact factor: 5.722

Review 6.  Circular RNAs: new biomarkers of chemoresistance in cancer.

Authors:  Jiaqi Wang; Yi Zhang; Lianyu Liu; Ting Yang; Jun Song
Journal:  Cancer Biol Med       Date:  2021-03-19       Impact factor: 4.248

Review 7.  Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives.

Authors:  Huan-Huan Chen; Tie-Ning Zhang; Qi-Jun Wu; Xin-Mei Huang; Yu-Hong Zhao
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

8.  Circ-SPG11 knockdown hampers IL-1β-induced osteoarthritis progression via targeting miR-337-3p/ADAMTS5.

Authors:  Yongqiang Liu; Qian Li; Zhida Gao; Fang Lei; Xuefeng Gao
Journal:  J Orthop Surg Res       Date:  2021-06-17       Impact factor: 2.359

9.  Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis.

Authors:  Jin Li; Xiaoping Qin; Ruishan Wu; Li Wan; Liang Zhang; Rui Liu
Journal:  J Cell Mol Med       Date:  2020-03-28       Impact factor: 5.310

10.  miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1.

Authors:  Kuan-Bing Chen; Wei Yang; Ying Xuan; Ai-Jun Lin
Journal:  Cell Death Dis       Date:  2021-07-28       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.